Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.
Montagna
E
E
Department of Medicine, Research Unit in Medical Senology. Electronic address: emilia.montagna@ieo.it.
Cancello
G
G
Department of Medicine, Research Unit in Medical Senology.
Torrisi
R
R
Department of Medicine, Research Unit in Medical Senology.
Rizzo
S
S
Division of Diagnostic Radiology, European Institute of Oncology, Milan, Italy.
Scarano
E
E
Department of Medicine, Research Unit in Medical Senology.
Colleoni
M
M
Department of Medicine, Research Unit in Medical Senology.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000069287:Capecitabine; D002291:Carcinoma, Papillary / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D000077341:Lapatinib; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011799:Quinazolines / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D016896:Treatment Outcome
D000069287:Capecitabine; D003841:Deoxycytidine; D005472:Fluorouracil; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases